<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03205137</url>
  </required_header>
  <id_info>
    <org_study_id>0502-0612</org_study_id>
    <nct_id>NCT03205137</nct_id>
  </id_info>
  <brief_title>Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice</brief_title>
  <official_title>Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy Based on Database Data in Real-world Japanese Therapeutic Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the medication adherence measured by PDC of&#xD;
      patients with FDC or double-pill combination therapy in real-world Japanese therapeutic&#xD;
      practice.The further objective of this study is how much influence the background of patients&#xD;
      to the adherence.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">January 11, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 11, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of days covered of patients treated with single- and double- combination therapy</measure>
    <time_frame>180 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Demographic and clinical characteristics of patients treated with single- and double combination</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">3275</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Telmisartan and hydrochlorothiazide group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan and amlodipine group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan+hydrochlorothiazide double-pill combination group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>telmisartan+amlodipine double-pill combination group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>subjects treated with telmisartan/hydrochlorothiazide</intervention_name>
    <description>subjects treated with telmisartan/hydrochlorothiazide</description>
    <arm_group_label>Telmisartan and hydrochlorothiazide group</arm_group_label>
    <other_name>MICARDIS, PRITOR, TELMISARTAN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subjects treated with Telmisartan and amlodipine</intervention_name>
    <description>Subjects treated with Telmisartan and amlodipine</description>
    <arm_group_label>Telmisartan and amlodipine group</arm_group_label>
    <other_name>MICARDIS, PRITOR, TELMISARTAN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group</intervention_name>
    <description>subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group</description>
    <arm_group_label>Telmisartan+hydrochlorothiazide double-pill combination group</arm_group_label>
    <other_name>MICARDIS, PRITOR, TELMISARTAN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>subjects treated with telmisartan+amlodipine double pill</intervention_name>
    <description>subjects treated with telmisartan+amlodipine double pill</description>
    <arm_group_label>telmisartan+amlodipine double-pill combination group</arm_group_label>
    <other_name>MICARDIS, PRITOR, TELMISARTAN</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Japan Medical Information Research Institute (JMIRI), Inc. prescription database is used.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with hypertension&#xD;
&#xD;
          -  Patients must have their first prescription (defined as index date*) for telmisartan&#xD;
             and hydrochlorothiazide or Micombi® between 01/07/2010 and 28/09/2010&#xD;
&#xD;
          -  Patients must have their first prescription (defined as index date*) for telmisartan&#xD;
             and amlodipine or Micamlo® between 10/12/2010 and 09/03/2011&#xD;
&#xD;
          -  Patients must have at least 180 days follow up verified by the presence of&#xD;
             prescription record&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who were under 40 years old at the time of enrolment&#xD;
&#xD;
          -  Patients who prescribed the study drugs less than 90 days during a follow up period of&#xD;
             180 days&#xD;
&#xD;
          -  Patients whose visits are less than 2 times during a follow up period of 180 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nippon Boehringer Ingelheim Co., Ltd.</name>
      <address>
        <city>Tokyo</city>
        <zip>141-6017</zip>
        <country>Japan</country>
      </address>
    </facility>
    <contact>
      <last_name>Seiichiro Nishimura</last_name>
      <phone>81364172157</phone>
      <email>seiichiro.nishimura@boehringer-ingelheim.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 29, 2017</study_first_submitted>
  <study_first_submitted_qc>June 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Telmisartan amlodipine combination</mesh_term>
    <mesh_term>Telmisartan, hydrochlorothiazide drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;.&#xD;
Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.&#xD;
The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://www.mystudywindow.com/msw/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

